Yang Jing, Liang Shuang, Liu Huahui, Hu Cai, Guan Sainan, Kang Haiyu, Xu Erjiao, Yan Ronghua
Department of Medical Ultrasonics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong Province, People's Republic of China.
Department of Radiology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, People's Republic of China.
J Hepatocell Carcinoma. 2023 Oct 18;10:1839-1848. doi: 10.2147/JHC.S424009. eCollection 2023.
To investigate the efficacy and safety of microwave ablation (MWA) assisted by ultrasound fusion imaging (FI) for primary and secondary liver cancers with a diameter of 3-7 cm.
A retrospective analysis was conducted on patients with primary and secondary liver cancers (3-7 cm) who underwent MWA with ultrasound FI assistance in our hospital from April 2020 to May 2022. Technical success, technique efficacy, local tumor progression (LTP), major complication, intrahepatic distant recurrence (IDR), and overall survival (OS) were assessed during the follow-up period. In addition, the ablation results of tumors between the medium-sized group (3.1-5.0 cm) and large-sized group (5.1-7.0 cm) were compared.
31 patients with 35 primary and secondary liver cancers were treated with MWA assisted by ultrasound FI. Complete ablation was achieved in 34 lesions with a technical success rate of 97.1%. Major complications occurred in 6.5% of patients (2/31), while no ablation-related deaths were reported. The median follow-up time of this study was 24 months (range:10 to 35 months). The technique efficacy rate was 97.1% (34/35), with LTP occurring in three lesions at a rate of 8.8% (3/34). The incidence of IDR was 38.7% (12/31) and the 2-year cumulative OS rate reached 96.7%. Moreover, there were no statistical differences in technique efficacy rate (p=0.286), LTP rate (p=0.328), major complication rate (p=0.503), IDR (p=0.857), and OS (p=0.118) between medium-sized group and large-sized group.
Ultrasound FI-assisted MWA has the potential to be an effective and safe therapeutic strategy for primary and secondary liver cancers ranging from 3-7 cm in size.
探讨超声融合成像（FI）辅助微波消融（MWA）治疗直径3 - 7 cm的原发性和继发性肝癌的疗效及安全性。
对2020年4月至2022年5月在我院接受超声FI辅助MWA治疗的原发性和继发性肝癌（直径3 - 7 cm）患者进行回顾性分析。在随访期间评估技术成功率、技术疗效、局部肿瘤进展（LTP）、主要并发症、肝内远处复发（IDR）和总生存期（OS）。此外，比较了中等大小组（3.1 - 5.0 cm）和大尺寸组（5.1 - 7.0 cm）肿瘤的消融结果。
31例患有35个原发性和继发性肝癌的患者接受了超声FI辅助的MWA治疗。34个病灶实现了完全消融，技术成功率为97.1%。6.5%的患者（2/31）发生了主要并发症，未报告与消融相关的死亡病例。本研究的中位随访时间为24个月（范围：10至35个月）。技术有效率为97.1%（34/35），3个病灶发生LTP，发生率为8.8%（3/34）。IDR发生率为38.7%（12/31），2年累积OS率达到96.7%。此外，中等大小组和大尺寸组在技术有效率（p = 0.286）、LTP率（p = 0.328）、主要并发症率（p = 0.503）、IDR（p = 0.857）和OS（p = 0.118）方面无统计学差异。
超声FI辅助MWA有可能成为治疗直径3 - 7 cm原发性和继发性肝癌的有效且安全的治疗策略。
